Author:
Lavacchi Daniele,Caliman Enrico,Rossi Gemma,Buttitta Eleonora,Botteri Cristina,Fancelli Sara,Pellegrini Elisa,Roviello Giandomenico,Pillozzi Serena,Antonuzzo Lorenzo
Subject
Pharmacology (medical),Pharmacology
Reference36 articles.
1. Ivosidenib in IDH1-mutant chemotherapy-refractory cholangiocarcinoma (ClarIDHy): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study;Abou-Alfa;The Lancet Oncology,2020
2. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study;Abou-Alfa;The Lancet Oncology,2020
3. Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-IDH1 cholangiocarcinoma;Aguado-Fraile;Future Oncology,2021
4. Cholangiocarcinoma 2020: the next horizon in mechanisms and management;Banales;Nature Reviews. Gastroenterology & Hepatology,2020
5. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology;Benson;Journal of the National Comprehensive Cancer Network,2021
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献